The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment (Rx) trends and attrition with lines of therapy in patients (pts) with advanced urothelial carcinoma (aUC).
 
Vinay Mathew Thomas
No Relationships to Disclose
 
Yeonjung Jo
No Relationships to Disclose
 
Nishita Tripathi
No Relationships to Disclose
 
Soumyajit Roy
Employment - Artera (I); Rush University
Research Funding - Swim Across America
 
Beverly Chigarira
No Relationships to Disclose
 
Emre Dal
No Relationships to Disclose
 
Georges Gebrael
No Relationships to Disclose
 
Chadi Hage Chehade
No Relationships to Disclose
 
Nicolas Sayegh
No Relationships to Disclose
 
Gliceida Galarza Fortuna
No Relationships to Disclose
 
Richard Ji
No Relationships to Disclose
 
Patrick Campbell
No Relationships to Disclose
 
Haoran Li
No Relationships to Disclose
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
Sumati Gupta
Stock and Other Ownership Interests - Salarius Pharmaceuticals (I)
Research Funding - Acrotech Biopharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/Lilly (Inst); Five Prime Therapeutics (Inst); Hoosier Cancer Research Network (Inst); Immunocore (Inst); Incyte (Inst); LSK BioPharma (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); QED Therapeutics (Inst); Rexahn Pharmaceuticals (Inst); Seagen (Inst); Viralytics (Inst)
Travel, Accommodations, Expenses - QED Therapeutics
(OPTIONAL) Uncompensated Relationships - Astellas Pharma
 
Umang Swami
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Exelixis; Imvax; Pfizer; Sanofi; Seagen
Research Funding - Exelixis (Inst); Janssen (Inst); Seattle Genetics/Astellas (Inst)